landscape

GLP-1 and Incretin Landscape: From Ozempic to Triple Agonists

A strategic overview of approved and pipeline incretin-based peptide therapeutics.

Published Aug 15, 2024 · Updated Aug 15, 2024 · Last reviewed Aug 15, 2024

Direct answer

The incretin landscape is dominated by approved GLP-1 and dual GIP/GLP-1 agents, with triple agonists and oral small molecules entering late-stage development.

Key takeaways

Semaglutide and tirzepatide have set efficacy and commercial benchmarks.
Retatrutide and cagrisema are the next potential blockbusters in phase 3.
Oral small molecules could expand access but face tolerability and adherence questions.

The GLP-1 receptor agonist class has transformed type 2 diabetes and obesity care. Semaglutide, marketed as Ozempic and Wegovy, demonstrated up to 15% weight loss in STEP 1 and cardiovascular benefit in SELECT. Tirzepatide's dual GIP/GLP-1 mechanism raised the bar further, with SURMOUNT-1 showing mean weight loss above 20%. Retatrutide adds glucagon receptor agonism and has reported up to 24% weight loss in phase 2. Cagrisema combines semaglutide with the amylin analogue cagrilintide and is in the REDEFINE phase 3 program. Oral entrants—including orforglipron, danuglipron, and GSBR-1290—aim to remove injection barriers but must match efficacy and safety profiles. Discontinued assets such as lotiglipron highlight liver safety risks for oral GLP-1 small molecules.

About this report

Author: Dr. Sarah Chen, Senior Biopharma Analyst
Scientific reviewer: Dr. Michael Patel, Healthcare Equity Research Director

Direct answer

Key takeaways

About this report

Related entities